Books
- Oncologic Virology, Idelson, Naples 1979
- Pathology of AIDS, Mapograf, Vibo Valentia 1991
- With cancer one can live, Mapograf, Vibo Valentia 1992
- AIDS: what we can do what we must know, Mapograf, Vibo Valentia 1994
- Pocket File Research Collection, Doctor’s, Naples 1997, 6th, 2003
- To Prevent Is To Win, Italia Sud, Rome 1998
- Bioethics and Culture of Prevention, Apẻiron, Bologna 2001
- Health without borders, Imago Media, Edition Piedimonte Matese, December 2004
- Health without borders, number 2, Rubbettino Editore, Soveria Mannelli 2007
- Safety no limits, Cassa Risparmio San Miniato 2008
- Health without borders, 4. Ed. Helicon Arezzo 2009.
- Medicina e Recenti Miracoli, Totus tuus edit. 2010.
- Sanità senza frontiere 5, ed. Chiron, 2012.
- Campania, terra di veleni, Denaro libri, 2012.
Abstracts
1) Effect of Various DNA Inhibitors on Synthesis of CF Antigens in Cell Cultures Infected with HSV. Intern. Congress of Chemoterapy, Tokio, August 1969.
2) Effect of DNA Inhibitors on Synthesis of Herpes Simplex Virus Antigens. (with P. Mastroeni). X Internat. Congress of Microbiol., Mexico City, August 1970.
3) Immunofluorescence of Virion and “Non Virion” Herpes Simplex Virus Antigens. (with G. Carrera). As above.
4) Current and future studies on Non Virion Herpes Antigens. VI Meeting European Tumor Virus Group Bad Vjmpfen, Heidelberg, April 1971.
5) Effect of two methisazone derivatives on herpes simplex virus replication. (with P. Mastroeni). VII Intern, Congress of Chemoth. Prague, August 1971.
6) Complement fixing nonvirion antigens in cells infected with different strains of herpes virus. VII Meeting of the European Tumor Virus Group (E.T.V.G.) Zierikzee. The Nederlands Sept. 25-27, 1972
7) Complement fixing reactivity of trypsin treated normal human cells with immunoglobulin against transformed and virus infected cells VII Meeting E.T.V.G., as above
8) Herpes simplex and genital virus Non-virion antigens: their use for determining the role of these viruses in etiology of some human cancers. (with A. Sabin). Annual Meeting of National Academy of Sciences. 1973-4-23 Washington D.C. (USA).
9) Result of recent studies on the role of the virus of Herpes simplex and Herpes genital in certain human cancers. (with A. Sabin). XIV European Symposium of Poliomemyelitis and other virus deseases. 1973-6-13 Ankara (Turkey).
10) Presence of Antibody for Herpes Non-virion Antigens in Sera of Cancer Patients. In Proceedings of the II Intern. Symposium on Cancer Detection and Prevention, Bologna. Excerpta Med. 275, 120, 1973.
11) Separation and analysis of herpesvirus genetic markers. Human Tumor Virus Meeting on the Herpesviruses Aug. 17-20, 1973. Cold Spring Harbor, New York.
12) Further studies on antibodies for herpesvirus nonvirion antigens and presence of herpesvirus genetic markers in cancer patients. The Eighth Meeting of the European Tumor Virus Group, Aviemore, Scotland ApriI2-5, 1974.
13) Antibodies for herpesvirus nonvirion antigens and herpes virus genetic markers in cancer patients. 2nd Scientific Meeting Group of Cooperation in Immunol. (G.C.I.). S. Gimignano 31 May. 1 June 1974.
14) Characterization of HSV nonvirion antigens: relation to squamous cell carcinomas.
Il Internat. Conference on Comparative Virology. Mt. Gabriel, Canada, Aug. 22-24, 1974.
15) Herpes Simplex Viruses l and 2 “Nonvirion» Antigens and Specific Antibodies in Immune Animals and Cancer Patients. II Int. Symp. on Oncogenesis and Herpesviruses. Nủrnberg October 14-16 1974,
16) Antibodies for Herpesvirus nonvirion antigens and herpesvirus genetic markers in cancer patients.XI Int. Cancer Congress. Firenze October 20-26 1974.
17) Nuclear “nonvirion” and soluble membrane antigens of herpes simplex virus: their relation to some human tumours. (with G. G. Giordano et al.). IX Meeting E.T.V.G. Mariehamn, Finland May 26-28 1975.
18) Herpes simplex virus antigens and their relation to some human cancers. (with G. Carrera). III Int. Congress for Virology. Madrid, Spain Sept. 10-12 1975.
19) Radioimmunological studies on nonvirion antigens induced by herpes simplex virus. (with R. Accinni and A. Bartorelli). Symp. on Herpesviruses Liblice. Castle, Czechoslovakia, June 1976.
20) Biochemical and Radioimmunological studies on nonvirion antigens of herpes simplex virus. (with R. Accinni et al.). III Intern. Symp. on Detection and Prevention of Cancer, New York, April 1976.
21) Purification of Herpes simplex virus (HSV l) by isoelectric focusing. (with R. Cocchiara et al.). Xth Meeting E.T.V.G. Grindelwald, Switzerland, Oct. 3-7 1976.
22) Nuclear «nonvirion” antigens of herpes simplex virus and their relation to some Human tumours. (with G. G. Giordano et al.). III Intern. Symp. on Detection and Prevention of Cancer, New York April 1976.
23) Purification of herpes simplex virus (HSV-1) by isolelectric focusing. (with R. Cocchiara et al.). III Intern. Symposium on Cancer Immunotheraphy, Bucharest 1-2 Sept. 1977.
24) Purification of herpes simplex virus tumor associated antigen (s) from infected cells and from human carcinomas (with R. Cocchiara et al.). 11 th Meeting European Tumor Virus Group, Balatonfured (Hungary) May 8-12 1978.
25) Purification and Characterization of an Antigen Extracted from Herpes Simplex Virus (HSV) Infected or Transformed Cells and from Certain Human Tumours. Herpes Virus Workshop, Cambridge (England). August 1978
26) Tryptic Peptide Analysis of Purified Herpes Simplex Virus (HSV) Tumour Associated Antigen (TAA) from Different Sources. (with R. Cocchiara et al.). Fourth Intern. Congress for Virology. The Hague, The Netherlands Aug. 30 -Sept. 6, 1978.
27) Enzylme-Iinked immunosorbent assay for herpes simplex virus tumours associated antigen. (with G. Flaminio et al.). Proc. XII International of Cancer Congress, Buenos Aires, Oct. 1978, Mesas de Trabajo.
28) The importance of ELISA in screening early antibody for HSV cervix uteri tumors associated antigens. (with G. Magli et al.). I Symp. It. Soc. of Gynaecologic Oncology, Rome, Dec. 1-2 1978.
29) Herpes simplex virus Tumor Associated Antigen (HSV-TAA) detected by the Enzyme-Linked Immunosorbent Assay (ELISA), VII Nat. Meeting of. Group. Coop. in Immunol., Cortona, June 15-17 1979.
30) HSV-induced nonvirion antigen in GPK cells multiplying in spinner flasks. (with G. Flaminio et al.). IV Herpesvirus Workshop, Cold Spring Harbor Laboratory (New York) , 28-8/2-9-1979.
31) Immunoenzymatic Assay for the screening of HSV-TAA in certain human tumours.
12° European Meeting Tumour Virus Group. SPA, Belgium, 10/14 Sept. 1979:
32) Herpes Simplex Virus induced Tumour Associated Antigen. As above
33) Perspectives and limits of an immunoenzymatic assay for HSV-TAA.
lntemational Symposium on Detection and Prevention of Cancer, London, July
26/31, 80.
34) Purification and characterization of type 2 HSV-TAA. As above
35) Monoclonal antibodies to Herpes Simplex Virus Tumor Associated Antigen (with
- Karpas e T. Wheeler).
lnternational Workshop on herpesviruses. Bologna (Italy). July 1980
36) Circulating Immunocomplexes (C1C) in Sera of Patients with Herpes Simplex Virus (HSV) – Associated Carcinomas. As above
37) Circulating Immunocomplexes (CIC) in sera of Patients with Herpes Simples Virus (HSV) – Associated Carcinomas. VI Meeting of the European Association for Cancer Research; Budapest – Hungary, 12/15-10/1981.
38) Human Tumor Antigens Inducing in Vivo Delaved Hypersensitivity and in vitro Mitogenic Activity. 13° International Cancer Congress. Seattle, Washington, USA, 8/15-9-1982.
39) Herpes Simplex Virus and Human Tumors. 14° Meeting of the European Tumor Virus Oroup; Druzhba-Varna Bulgaria; 24/28-10-1982.
40) Virological Investigations of Young Children with Acute Respiratory Syndrome Associated with Respiratory Syncytial Virus (RSV).
The Int. Symposium on Medical Virology. Disneyland Hotel, Anaheim (Los Angeles) California, 2/4-12-1982.
41) Quantitative Determination of Human CMV IgG Antibodies by Solid Phase Enzyme Immunoassay (ELISA): Comparison with CF test. As above
42) HSV-TAF purified by column and analytical isoelectric focusing. 6th lnternational Symposium on Prevention and Detection of Cancer, Wien. 26/ 29 Nov. 1984.
43)Safety of Hepatitis B vaccine: lack of evidence of AlDS agents transmission;
First international meeting of AVIS: ” AIDS: Diagnosis, prevention and therapy, advances and prospectives in virus research”, 1985-12-6, Naples.
44) Prevalence of antibodies to AIDS associated retroviruses on the Naples area; as above
45) HBV as possible cofactor for AIDS. Symposium Praesidium. “XI Dies ItaJico-Jugoslavici Medicinae Destinati, 1986-5-30, Dubrovnik, Jugoslavia.
46) Viruses and Immunodeficiences. Inter. Symposium on “Regulation of
Mammallian CeII, 1987-9-27, Capri (NA).
47) Monoclonal antibody for tumor associated antigens induced by Herpes Simplex Virus. International Congress Advances in Management of Malignancies”, 1988-5-3, Ascoli Piceno.
48) Behaviour of beta2m in some oncoemopathies. XV World Congress of Anatomic and Clinical Pathology, 1989-5-16 Firenze.
49) Epidemiological, serological, evolution aspects of HIV infection and related malignancies within Naples area (Jan ’86 – Dec. ’89).
II Intemational Congress Advances in Management or Malignancies”, 1990-5-28, Ascoli Piceno.
50) Search for tumor antigens to be used for active specific immunotherapy. As above
51) Histochemistry and Immunohistochemistry in the diagnosis of prostatic carcinoma. As above
52) IgE Ferritine: Markers of relapse in Hodgkin disease. As above
53) Naples Group C Centre for Anonimous HIV Screening. VI International Conrerence on AIDS, 1990-6-2, San Francisco (USA).
54) In vitro toxicity and immunogenicity of seven endodontic materials. Meeting of Int. Assoc. of Dental Research I.A.D.R.), 1992-7-1, Glasgow, Scotland.
55) Opportunistic viraI infection in 124 patients recognised by celI culture virus isolation. VIII International Conference on AIDS, 1992-7-19, Amsterdam.
56) Seroepidemiologic pattern of HCV infection in Campania during the first six months of 1992. Third International Conference on Current Trends in ChronicalIy Evolving Virai Hepatitis, 1992-10-4, Pisa.
57) A fast and sensitive technique for cytomegalovirus isolation from liquid by celI culture. 6th European Congress or Clinical Microbiology and Infectious Disease, 1993-3-28, Seville (Spain).
58) Importance of p24 antigen in the detection of HIV infection.
IX International Conference on AIDS, 1993-6-6, Berlin.
59) Ratio CD5/CD8 and percentage in HIV infected people.
H1V infection in drug addicts correlated to HBV and HCV. As above
60) Antigenic Regions of Tumor Liberated Protein Complexes and Antibodies Against the Same.
Advances in Management of Malignancies, 1993-12-6/10, Pisa.
61) Lung Carcinoma Histopathologic Approaches for a Prognostic Evaluation. As above
62) Screening of HTLV-I in Drug Addicts from Campania Region. As above
63) Ratio CD5/CD8 in HIV infected people: fourth European Conference of Clinical Aspects and Treatment of HIV lnfection, 1994-3-16 Milano.
64) Interactions of human immunodeficiency virus and the hepatotropic viruses in drug addicts. lnternational Congress Biotech ’94 on AIDS, 1994-4-10 Firenze.
65) Ethics and Med. Legal problems in HIV Seropositivity communication. Tenth International Conference on AIDS, 1994-8-7, Yokohama (Japan).
66) Hepatitis viruses in HIV infected intravenous drug users. Fourth International Conference on Current Trends in Chronical EvoIving ViraI Hepatitis, 1995-3-30, Perugia.
67) Coinfection of Hepatitis viruses and HIV in intravenous drug users.
Third International Conference on AIDS in Asia and the Pacific. The Fifth National AIDS Seminar in Thailand, 1995-9-17/21 , Chiang Mai (Thailand).
68) HTLV 1/2 and H1V infection in drug addicts (DA). 3rd Conference on Retroviruses and Opportunistic lnfections, 1996-1-28/31 Washington, DC (USA).
69) Relationship between HCV genotypes and antibody reactivity. Xth International Congress of Virology, 1996-8-11/16, Gerusalemme (Israele).
70) Further study on HCV genotypes of Naples province. 6th International Conference on Laboratory Medicine, 1996-9-13/16, Capri (NA).
71) Angiogenesis and vasculoinvasion in the colon adenocarcinoma: histopathologic approach. “Development cell differentiation and cancer”, 1996-9-28/10-2, Pisa
72) Elisa to detect anti-TLP (tumor liberated protein) antibody from lung cancer human sera. Comunicazione. Advances in Management or Malignancies, 1996-11-25/27, Pisa.
73) Development of TLP for Cancer First Joint International Conference “Gene Targets ror Cancer Treatment”, 1997-6-3/6, Capri (NA).
74) What correlation between HIV RNA and HCV RNA coinfection. Abstract (in coll.).
Inaugural Meeting or the European Society for Clinical Virology “Progress in Clinical Virology III”, 1997-9- 7/10, Bologna.
75) Utility or HIV-RNA as progression Marker in HIV infection, 4th International Congress on AIDS in Asia and the Paciflc, 1997 -I0- 25/29, Manila (Philiippines).
76) Decrease of HIV -RNA viral load below 200 copies/mi relates to basai viral load after combination therapy. 12th World AIDS Conference, Geneva (Switzerland) June 28- July 3, 1998.
77) Overview of the Lung Tumor Liberated Protein (TLP): Characterization of the Genetic Immunologic Profile. Biomedicine & pharmacotherapy 52 (7/8) :338, 1998.
78) Aims and perspectives for TLP. New Dimensions in Cancer Biology and Therapy. The 2nd Joint Intemational Conference, III session ViraI Etiology, Capri, Sept. 1998.
79) Relation between viraI load and different T cell population counts in HIV infection. AIDS and Related Sindroms . XII National Meeting. Genova 22/25-11-1998.
80) HCV Genotypes and Antibodies Reactivity: what’s relation? 34th Annual Meeting of the European Association for Study of the Liver. Napoli, 8-12 April 1999
81) Tumor Liberated Protein (TLP): its Potential for Diagnosis. IFCC-WorldLab ’99 Congress – Firenze, June 1999.
82) Evaluation of a new method of HCV RNA Real Time. International Workshop on Viruses Immunity and Disease, Napoli October 1999.
83) Further Evaluation of HAART Efficacy by the Ultrasensitive PCR Method for the Quantitation of HIV-I RNA in Human-Plasma. Seventh European Conference on Clinical Aspects and Treatment of HIV Infection. 10-23/27-1999, Lisboa (Portugal).
84) EI and E2 antibodies in HCV Chronic Hepatitis. Virology Meeting of Three Society,
Stockolm Feb. 3-5, 2000.
85) Interleukin 2 production in Chronic HCV Infection: what correlation? Virology Meeting of Three Society, Stockolm Feb. 3-5, 2000.
86) Immunohistochemical evaluation of endothelial damage by angioinvasivity. Biomedicine & Pharmacotherapy, voI 54 n. 8-9 October 2000, page 445.
87) Monoclonal antibody to Tumor Liberated Protein (TLP): Serological and Immunohisto-chemical studies. Biomedicine & Pharmaco-therapy voI54 n. 8-9 October 2000, page 463.
88) Characterization of fragment containing a putative TLP cDNA sequence. Biomedicine & Pharmacotherapy voI 54 n. 8-9 October 2000, 463-464.
89) Production and characterization o[ anti-TLP-derived peptide (RTNKEASIC) monoclonal antibodies. Biomedicine & Pharmacotherapy voI 54 n. 8-9 October 2000, page 464.
90) No evidence of pig endogenous retrovirus infection in human susceptible cell lines in vitro exposed to human plasma perfused in bioartificial liver: preliminary results. II Int. Workshop on Immunity and viruses, 22-24, Feb.2001, Napoli page 55.
91) TTV Antibodies in patients with ECA HCV correlated Il Int. Workshop on Immunity
and Viruses, 22-24 Feb. 2001, Napoli page 66.
92) Increasing HIV Incidence in Women, Proc. General Assembly United Nations, New York
June 2001.
93) Evaluation of a new test for the determination of the HCV genotypes. 5th Annual Meeting ESCV, 2-5 Sept 2001 Lahti, Finland.
94) Determination or HBV polymerasis gene mutations in HBV ECA patients treated and naive. VII International Conference on Current Trends in Chronically Evolving ViraI Hepatitis, Sept. 23-25, 2001. Florence, Italy.
95) HCV-RNA ViraI load and HCV genotype: what correlation? VII Intern. Conference Current Trends in Clinically Evolving ViraI Hepatitis, Sept. 23-25,2001,Florence, Italy.
96) HIV protease and reverse transcriptase mutation identification.(with C. Esposito. N. Cuomo. F. Morelli,A. Di Spirito. M. lannece. P. Rosario. R. Pempinello.). The World of Microbs. Congress of The lnternational Union of Microbiological Societies (IUMS), Paris (France). 27/7-1/8/2002.
97) Progress and new hope in the fight against cancer: novel developments in early detection of lung cancer. Biomed Pharmacother 56:359-60. 2002.
98) “HIV mutation study during antiretroviral treatment”
Winter Meeting – SPV /ESCV Joint Meeting of the Sociedade Portuguesa de Virologie and the European Society for Clinical Virology. Estoril (Portugal). 9-111112003, ESCV News letter, 13 June 2003. page 67.
99) The threat of Bioterrorism 3rd International Workshop on Immunology and Infectious Diseases. Infectious diseases from genetic implications to clinical aspects Napoli 8-10 June 2004.
100) Antiretroviral Treatment and HIV-l Mutation. Second European Congress of Virology Eurovirology 2004, Madrid, Spain, September 5-9 2004
- Tumor Liberated Protein from Cancer and Perspectives for Immunotherapy.
BIT Life Sciences 2° Annual World Vaccine Congress – Beijing, March 2010
- AntiTLP (tumor Liberated Protein) Antibodies for Lung Cancer Cells and Identification of Whole Sequence of TLP. Search for the Cell Gene.
Theme: The Future of Global Vaccines. Beijing, March 2011
- Tumor Liberated Protein and Peptide Search for the Cell Gene and its Whole Sequence
Theme: New Leaders in Protein and Peptide Science. Beijing, March 2011
- Antibodies against Non Small Lung Cancer Cells and their Role in Diagnosis and Immunotherapy of Lung Cancer.
Theme: Discovery, Partnering to Market. Beijing, March 2011
- Fragments of Tumor Liberated Protein from Lung Cancer to Stimulate Immune Response to Attack Existing Tumors.
Theme: Collaborative Actions against Cancer. Dalian (China), May 2011
- Emerging Viral Agents at Risk in Global Health Approches to Early Diagnosis and Prompt.
Theme: Computational Biology. Las Vegas (USA), July 2011
- Tracking the 2009 H1N1 influenza virus in the Italian region Campania.
PubMed 21928341
- Peptide Search in the Tumor Liberated Protein (TLP) from Non Small Cell Lung (NSCL) Cancer.
BIT’s 4° Annual World Congress of Biosoft, Beijing, March 2012.